CKDCE2

Disclosures of Relevant Financial Relationships
It is the policy of AcademicCME that all faculty, instructors, and planners disclose relevant financial relationships with ineligible companies. Planners have no relevant financial relationships with ineligible companies to disclose related to this activity. Faculty have disclosed the following relevant financial relationships. All relevant financial relationships have been mitigated.

Faculty

Relationship Identified With:

Edgar Lerma, MD

Consultant/Advisor: Vifor; Otsuka; Bayer

Speaker’s Bureau: AstraZeneca; Bayer; Otsuka

Planners and Peer Reviewers
Timothy Hayes, MD, PhD; Charles V. Pollack Jr., MD; Kim Cheramie, MSN, RN-BC; Patrick Hayes and Chelsey Simonds hereby state that they do not have any relevant financial relationships to products or devices with any commercial interests related to the content of this activity.

Accreditation Statement
In support of improving patient care, AcademicCME is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Credit Designation Statements
AcademicCME designates this enduring material for a maximum of 0.50 AMA PRA Category 1 Credits^TM.
AcademicCME designates this enduring material for a maximum of 0.50 CNE Contact Hours.
AcademicCME designates this continuing education activity for 0.50 CPE Contact Hours (0.05 CEUs) of continuing pharmacy education credit (UAN # JA4008190-0000-24-017-H01-P.)
Learners should only claim credit commensurate with the extent of their participation.

This activity has been supported by an independent educational grant from Travere Therapeutics.

Name*

First NameLast Name
Email*
example@example.com
I am a:

PhysicianNP or PANursePharmacistOther
If Physician, I am primarily a:

Primary care providerNephrologistOther internistGeneral surgeonOther surgeonEmergency medicine physicianOther
If Pharmacist, DOB:*

MonthDayYear
Date
If Pharmacist, NABP ID#:*
I work primarily in:

United StatesCanadaEuropean UnionGreat BritainLatin AmericaAsiaAustralia/New ZealandOther
I work primarily in the:

Inpatient settingOutpatient settingOther
I engaged with this program via:

PodcastVideo podcastVideo podcast (first time using for CE/CME)YouTube.ceYouTube (first time using for CE/CME)
I would recommend this program and format to my colleagues.

YesNo
I am aware of CE/CME courses available on Twitter from @ckd_ce.

TrueFalse
1. What is the most important aspect for a primary care provider to monitor in IgAN patients after referral to a nephrologist?*

a. Creatinine clearanceb. Blood pressure and proteinuria levelsc. Dialysis scheduled. Blood glucose levels
2. What is one key action a PCP can take to monitor disease progression in a patient with IgAN following nephrology referral?*

a. Repeating renal biopsy annuallyb. Regular monitoring of serum creatinine, GFR, and proteinuriac. Performing monthly dialysisd. Only following nephrologist recommendations, with no further monitoring
Attestation to Time Spent on Activity:
AcademicCME designates this activity for a maximum of 0.50 AMA PRA Category 1 Credits^TM, 0.50 CNE Contact Hours, or 0.50 CPE Contact Hours (0.05 CEUs) UAN # JA4008190-0000-24-017-H01-P for participation in the full educational activity.
I participated in this activity and claim:*

AMA PRA Category 1 Credits^TMCNE Contact HoursCPE Contact Hours (CEUs)
Date

MonthDayYear
Date
Should be Empty: